LONDON (Reuters) -Novo Nordisk's late bid to hijack Pfizer's takeover of U. obesity biotech Metsera marks an aggressive shift ...
1hon MSN
Urgent warning after severely anorexic woman was prescribed weight loss jab by online pharmacy
A severely anorexic young woman was prescribed blockbuster weight loss jab Wegovy by one of the UK's biggest online ...
Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...
Eli Lilly raised its full-year profit and revenue forecasts on Thursday as strong international demand for weight-loss drugs ...
Americans are getting slimmer; Gallup says the obesity rate has decreased along with increased use of weight loss drugs such ...
Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...
Hundreds of additional employees are reportedly slated for “temporary layoffs.” And GM has recently moved to downsize other ...
Novo Nordisk launched a bid valued at up to $9 billion for obesity-drug developer Metsera, hoping to trump an already agreed-on deal Pfizer made for the U.S. company last month.
Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...
Denmark's Novo Nordisk launched a rival bid for U. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...
The Wegovy and Ozempic maker’s offer comes after Pfizer last month agreed to a lower deal to acquire the Nasdaq-listed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback